Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

At a glance

Content :

Sanofi in the UK - at a glance

Sanofi's operations in the UK have, for over 40 years, been integral to our global success. Our aim is to protect, enable and support tens of millions of people across the UK & Ireland in the moments that matter, helping people live longer, live better and experience life to the fullest. With over 1,750 employees in the UK, we have a strong presence to support the patients’ needs.

Sanofi is made up of five Global Business Units (GBUs): Diabetes & Cardiovascular, General Medicines & Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.

General Medicines & Emerging Markets: Providing solutions for a diverse set of patient needs

We touch the lives of one in three people in the UK with our medicines. We have 135 treatments spanning 13 therapy areas. We are committed to supporting and driving people’s engagement in their own health through tailored services and solutions. An example of this is the provision of dedicated educational resources, sharps bins, and demonstration materials to equip and empower people to effectively manage their condition

  • 135 treatments
  • Diverse therapeutic areas including: Allergy treatments, pain, mental health, thrombosis, renal, epilepsy, fertility and urology

Diabetes & Cardiovascular: Tackling chronic diseases with a large impact on our society

In the UK, 3.3 million people suffer from diabetes and over 700 people are diagnosed with the disease every day1. Over seven million people suffer from cardiovascular disease (CVD) and 400 people lose their lives to the disease every day2. We support over 250,000 people with diabetes every month and have significantly invested in the research and development of new therapeutic options for people whose ‘bad’ cholesterol is not controlled by other existing cholesterol-lowering medicines. We invest over £1 million every year in patient support and disease awareness programmes such as Heart of the Family. We are committed to supporting and driving people’s engagement in their own health through tailored services and solutions. An example of this is the provision of a patient support programme featuring nurse support, treatment reminders and access to educational resources to help enrolled patients achieve their cholesterol goals, and complement existing care provided by the NHS

  • 2015 net sales: €126.2M/ £102.2M*
  • Seven treatments
  • Focus areas include: Type 1 and type 2 diabetes and cardiovascular disease, including familial hypercholesterolemia (FH)

Sanofi Pasteur: We believe in a world where no one suffers or dies from a vaccine-preventable disease

In the UK, on average, 600 people die each year from complications of flu, with pregnant women and older people being among those at greatest risk. In some years the number of deaths has risen to over 10,0003. We have a history of innovation; Louis Pasteur administered the first vaccine for rabies in 1885. We are a world leader in the seasonal flu vaccine, and we provide more than one billion doses of high quality vaccines each year.

  • Focus areas include: Paediatric, flu, boosters, meningitis and travel vaccines

Sanofi Genzyme: Focus on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families

We have a strong heritage; 35 years of dedication to developing treatments for people with rare diseases, with patient populations ranging from 170 to 100,000. Sanofi Genzyme has been awarded two Prix Galien recognitions in the last six years, in the orphan and innovative medicine categories. In 2015, the company conducted 35 programmes in collaboration with patient associations to raise awareness and to provide training and learning to patients. Sanofi is committed to supporting and driving people’s engagement in their own health through tailored services and solutions. An example of this is the provision of post-prescription support for people with multiple sclerosis at every step of their treatment, including an 'at-home' phlebotomy service, a personalised one-to-one support programme and home delivery

  • 19 treatments
  • Focus areas include: Therapeutic areas with high unmet need, including multiple sclerosis, rare diseases, immunology and oncology

Consumer Healthcare: Dedicating expertise to provide treatments to improve self-care and public health

In the UK, one in four people suffer from nasal allergies4. Back pain is the largest single cause of disability, with lower back pain alone accounting for 11% of the total disability of the UK population5. We have a more than 50-year heritage in consumer healthcare, and an industry-leading portfolio of products including those in digestive health, pain care, allergy and vitamins and mineral supplements. We invest in making products accessible, with regulatory status switches including prescription to pharmacy and pharmacy to General Sales List (GSL). We are a top 10 player in OTC (no. 10: in the UK and no. 6: in Ireland)

  • Focus areas include: Digestive health, pain care, allergy, and vitamins and mineral supplements

*GBP calculated using the following 2015 conversion rate: €1 to £0.81

Date of preparation: October 2017 - Job bag number: SAGB.SA.17.09.1197b

Updated: October 16, 2017